BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  COVID-19 News: 100% Efficacy for Kids 12-17, Misconception of COVID-19 and Hearing Loss and More

  Please check out the biopharma industry’s COVID-19 stories that are trending for May 25, 2021.

  May 25, 2021

   · 

  4 min read

   · 

  BioSpace Editorial Staff
• 

  Companies Unlocking a New Class of Cancer Therapies with Sensitive METTL3 Tuning

  University of Cambridge researchers published the first preclinical validation for a novel therapeutic strategy targeting epitranscriptomic modifiers of RNA, opening the door for spinout STORM Therapeutics’ AML therapy–and potentially much more.

  May 25, 2021

   · 

  5 min read

   · 

  Mark Zipkin
• 

  Deals

  UK Says ‘Not So Fast’ on AstraZeneca’s $39 Billion Alexion Acquisition

  The UK’s Competition and Markets Authority (CMA) will determine if the deal is anti-competitive.

  May 25, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Xilio and Merck Partner on Anti-CTLA-4 Antibody/Keytruda Combo in Solid Tumors

  The clinical trial, which will be conducted by Xilio, will assess XTX101’s safety and efficacy as a monotherapy, as well as in combination with Keytruda, in solid tumors.

  May 25, 2021

   · 

  2 min read

   · 

  Ellen Bombela
• 

  Drug Development

  FDA Clears AskBio’s AAV Gene Therapy for Muscular Dystrophy to Enter Phase I/II

  LION-101 is a novel recombinant AAV being developed as a one-time intravenous infusion for the treatment of adult and adolescent patients with Limb-Girdle Muscular Dystrophy Type 2I/R9.

  May 25, 2021

   · 

  2 min read

   · 

  Heather McKenzie
• 

  FDA

  Ocugen Closes in on Seeking EUA for India-Developed COVID-19 Vaccine

  Ocugen submitted a “Master File” to the U.S. FDA for COVAXIN, the vaccine that has already received authorization in India for people ages 12 and above.

  May 25, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  Gene Therapy Continues Edging into the Mainstream

  Gene therapy is still very much cutting-edge with the potential to cure incurable genetic diseases. Here’s some recent news in the space.

  May 25, 2021

   · 

  4 min read

   · 

  Mark Terry
• 

  Drug Development

  AbbVie Hopefuls Skyrizi and Rinvoq Show Promise in Quest to Succeed Humira

  AbbVie is aiming Skyrizi and Rinvoq at various indications to augment expected declines in the use of its $20-billion-generating-powerhouse Humira, which will lose patent protection in 2023.

  May 25, 2021

   · 

  3 min read

   · 

  Alex Keown
• 

  FDA

  Reports of Hospitalized Wuhan Scientists Ignite Doubt Over Pandemic’s Origins

  The White House has also called for an independent investigation and more information from China about the pandemic’s origins.

  May 25, 2021

   · 

  5 min read

   · 

  Mark Terry
• 

  Deals

  Sana Aims to Hire 100 New Employees On Heels of $587 Million IPO

  The additional 100 people will be placed in Seattle, San Francisco, and Cambridge, Mass. by the end of the year.

  May 25, 2021

   · 

  2 min read

   · 

  Alex Keown